ABRDN LIFE SCIENCES INVESTOR (HQL) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:HQL - US87911K1007
17.29 USD
+0.04 (+0.23%)
16.7 USD
-0.59 (-3.41%)
Overall HQL gets a fundamental rating of 2 out of 10. We evaluated HQL against 0 industry peers in the Unkown industry. While HQL seems to be doing ok healthwise, there are quite some concerns on its profitability. HQL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year HQL has reported negative net income.
Of the past 5 years HQL 4 years were profitable.
HQL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.92% | ||
| ROE | -3.03% | ||
| ROIC | N/A |
ROA(3y)-0.41%
ROA(5y)7.25%
ROE(3y)-0.75%
ROE(5y)7.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of HQL has declined.
HQL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-8.83%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HQL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HQL has more shares outstanding
HQL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 19.82 indicates that HQL is not in any danger for bankruptcy at the moment.
HQL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.82 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
HQL has a Current Ratio of 0.42. This is a bad value and indicates that HQL is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.42 indicates that HQL may have some problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.42 | ||
| Quick Ratio | 0.42 |
3. Growth
3.1 Past
The earnings per share for HQL have decreased strongly by -129.58% in the last year.
HQL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.08% yearly.
The Revenue for HQL has decreased by -10.15% in the past year. This is quite bad
Measured over the past years, HQL shows a quite strong growth in Revenue. The Revenue has been growing by 10.28% on average per year.
EPS 1Y (TTM)-129.58%
EPS 3Y5.08%
EPS 5YN/A
EPS Q2Q%-189.13%
Revenue 1Y (TTM)-10.15%
Revenue growth 3Y20.23%
Revenue growth 5Y10.28%
Sales Q2Q%-34.3%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HQL. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 10.53%, HQL is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 1.87, HQL pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 10.53% |
5.2 History
HQL has been paying a dividend for at least 10 years, so it has a reliable track record.
HQL has decreased its dividend recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
17.29
+0.04 (+0.23%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners31.14%
Inst Owner Change-2.64%
Ins Owners0.01%
Ins Owner Change3.48%
Market Cap499.16M
Revenue(TTM)3.27M
Net Income(TTM)-12.00M
Analysts0
Price TargetN/A
Short Float %0.29%
Short Ratio0.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 10.53% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 152.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.26 | ||
| P/tB | 1.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.42
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.11
BVpS13.72
TBVpS13.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.92% | ||
| ROE | -3.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-0.41%
ROA(5y)7.25%
ROE(3y)-0.75%
ROE(5y)7.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-8.83%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.42 | ||
| Quick Ratio | 0.42 | ||
| Altman-Z | 19.82 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.58%
EPS 3Y5.08%
EPS 5YN/A
EPS Q2Q%-189.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.15%
Revenue growth 3Y20.23%
Revenue growth 5Y10.28%
Sales Q2Q%-34.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
ABRDN LIFE SCIENCES INVESTOR / HQL FAQ
What does ABRDN LIFE SCIENCES INVESTOR do?
abrdn Life Sciences Investors is a US-based company operating in industry. The company is headquartered in Philadelphia, Pennsylvania. abrdn Life Sciences Investors (the Fund) is a non-diversified closed-end management investment company. The Fund’s investment objective is to seek long-term capital appreciation by investing primarily in securities of life sciences companies. The Fund invests primarily in securities of public and private companies. The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund’s investment adviser is abrdn Inc.
Can you provide the latest stock price for ABRDN LIFE SCIENCES INVESTOR?
The current stock price of HQL is 17.29 USD. The price increased by 0.23% in the last trading session.
What is the ChartMill rating of ABRDN LIFE SCIENCES INVESTOR stock?
HQL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.